The Challenge of NCE Attrition: How to Decrease the Mortality Rate in Your Pipeline
Untitled Document

The Challenge of NCE Attrition: How to Decrease the Mortality Rate in Your Pipeline

December 5, 2017

8:00 a.m. PST / 11:00 a.m. EST / 16:00 GMT / 17:00 CET

Register Now
 
 

Overview

 

Drug discovery and development success rates have not improved over the last 15-20 years, and by some measures, especially those for New Chemical Entities (NCEs), the success rates are declining. NCE success rates through preclinical testing are around 50%, and from Phase 1 to FDA approval they are around 6%. This puts overall NCE success rates from preclinical to FDA approval at around 3%! This webinar will briefly review current data on pipeline success rates and then discuss the three highest causes for NCEs attrition and potential innovations that can improve NCEs survival, leading to more effective and efficient drug discovery and development.

Brought to you by:

 

Participants Will Learn:

 

• How to create a more effective and efficient drug discovery and development pipeline

• Recent trends in pharma pipeline success

• Greatest causes of NME attrition

• Novel approaches to improve NME survival

Who Should Attend:

 

• Pharmaceutical executives

• Pharmaceutical R&D Directors/Managers

• Research scientists

 

Speaker

 
Dr. Kelvin Cooper, Ph.D.,
Previous Sr. Vice President
Pfizer
 

Moderator

 
Celia Henry Arnaud
Senior Editor
CEN
 

Register Now